FiercePharma

Novartis drug Signifor® LAR recommended by CHMP for EU approval to treat patients with rare hormonal disorder acromegaly

Acromegaly is an endocrine disorder caused by elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels[1] Signifor LAR (pasireotide) represents a potential new option for ...
FierceBiotech

Novartis gains FDA approval for Signifor® LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder

Acromegaly is an endocrine disorder caused by elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels[1] Signifor LAR, a next-generation somatostatin analog, provides a new option ...
FiercePharma

Phase III Novartis data show potential benefit of Afinitor® plus Sandostatin® LAR® in patients with advanced neuroendocrine tumo

Everolimus plus octreotide LAR extended time without tumor growth from 11.3 to 16.4 months versus octreotide LAR alone in advanced NET (carcinoid) patients[1] The study did not reach its primary ...
Nature

LAR receptor protein tyrosine phosphatases in the development and maintenance of excitatory synapses

Leukocyte common antigen–related (LAR) family receptor protein tyrosine phosphatases (LAR-RPTP) bind to liprin-α (SYD2) and are implicated in axon guidance. We report that LAR-RPTP is concentrated in ...